GenScript
About GenScript
GenScript Biotech Corporation (HK.1548) is the world‘s leading technology and service provider of life science R&D and manufacture. Built upon its solid gene synthesis technology, GenScript Biotech is divided into four major platforms including the life science service and product platform, the biologics contract development and manufacturing organization (CDMO) platform, the global cell therapy platform and the industrial synthesis biological product platform.
As the world's leading biology research service company, GenScript offers comprehensive life sciences research services and products including custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development, catalog antibodies, catalog kits and eStain and eBlot. In addition, GenScript provides preclinical drug development services, including in vitro pharmacology, in vivo pharmacology, and antibody/protein engineering services. GenScript Biotech's business operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and Ireland.
Our Vision
Become the Most Trustworthy Biotech Company in the World
Provide high quality products and services for customers, offer development opportunities that help our employees reach their career and professional goals, and create long-term value for society.
Our Mission
Make Human and Nature Healthier Through Biotechnology
Build world-class biotech platforms for R&D in synthetic biology and healthcare to facilitate life science research, develop innovative products, address environmental issues, and treat critical illnesses for the well-being of mankind.
54 articles about GenScript
-
GenScript Debuts GenTitan Gene Fragments Service to Expedite Gene Synthesis at Lower Cost
5/23/2023
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, announced the debut of its breakthrough GenTitan™ Gene Fragments Synthesis service.
-
GenScript to Debut Expanded Synthetic Biology Product Line at SynBioBeta 2023
5/22/2023
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is a sponsor of this year's SynBioBeta Conference in Oakland, California.
-
GenScript Expands Peptide and Oligonucleotide Production Facility in China
5/18/2023
GenScript's new life-science building in Zhenjiang, Jiangsu, China spans 91,310 sq. ft. and is ISO 9001 certified; highly automated clean-room facilities offer fast-turnaround, high-purity oligonucleotide and peptide synthesis service for R&D and preclinical applications.
-
GenScript Expands Footprint in Singapore to Provide Premium Gene Synthesis Service
2/28/2023
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, announced the expansion of its Singapore facility to provide a premium gene synthesis service.
-
Cell and Gene Therapy Companies Leverage GenScript's cGMP sgRNA Capability to Accelerate Speed to Market
12/15/2022
GenScript USA Inc. recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies.
-
GenScript Partners with Allozymes to Accelerate Protein Discovery and Target Identification
12/7/2022
GenScript Biotech Corporation, the world's leading provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, to dramatically accelerate the enzyme discovery and development process.
-
GenScript Named a BioSpace 2023 Best Place to Work
11/16/2022
GenScript USA Inc., the world's leading life-science research tools and services provider, has been named a BioSpace 2023 Best Place to Work.
-
GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study
9/22/2022
GenScript USA Inc. is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods.
-
GenScript USA Responds to Monkeypox Public-Health Emergency with Real-Time PCR Test
8/18/2022
GenScript USA Inc., a subsidiary of GenScript Biotech Corporation, a world-leading biotechnology company, announced the immediate availability of a monkeypox virus PCR test kit.
-
GenScript Launches Expedited mRNA Service for Research and Pre-Clinical Applications
8/17/2022
GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams.
-
GenScript to Host 2nd Annual Gene & Cell Engineering Virtual Summit
7/26/2022
GenScript USA Inc., the world's leading life-science research tools and services provider, announced its second annual GenScript Gene & Cell Engineering Virtual Summit, which will feature in-depth discussions and research presentations on the crucial gene-synthesis and cell-editing technologies that are transforming scientific and biomedical research.
-
GenScript USA Enters Distribution Agreement with EUROIMMUN US for cPass SARS-CoV-2 Neutralizing Antibody Detection Kit
5/26/2022
GenScript USA Inc., a subsidiary of GenScript Biotech Corporation, a world-leading biotechnology company, has reached an agreement with EUROIMMUN US Inc., a PerkinElmer Company, for the distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in the United States and Canada.
-
Genscript Biotech Reports 2021 Annual Results
3/20/2022
GenScript Biotech, the world's leading biotech company, announces its annual results as of December 31, 2021.
-
GenScript Launches Closed-End Double-Stranded DNA Service for CRISPR
11/12/2021
GenScript USA Inc announced today that it has launched the GenWand™ Double-Stranded DNA (dsDNA) Service for the manufacture of CRISPR knock-in homology- directed repair (HDR) templates in T cell engineering.
-
GenScript Expands Commercial Production in U.S. with State-of-the-Art Gene Synthesis Center
11/2/2021
GenScript USA Inc., the world's leading life science research tools and services provider, announced that it has opened a larger than 50,000-square-foot facility for highly automated gene synthesis and plasmid preparation services near its U.S. headquarters in Piscataway, New Jersey.
-
GenScript to Host Gene & Cell Engineering Virtual Summit
7/13/2021
GenScript® , the world's leading life science service provider, announced today the first GenScript Gene & Cell Engineering Virtual Summit.
-
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement
5/12/2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr.
-
GenScript Launches Research-Grade Lentiviral Vector Packaging Service
4/28/2021
UCSF collaborates with GenScript to screen drug candidates for infectious diseases using Lentiviral Vector Packaging Service
-
GenScript Receives FDA Emergency Use Authorization for Use of cPass(TM) SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
2/11/2021
GenScript USA Inc ., the world's leading life science research tools and services provider, announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration
-
Two months after he was stepped down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang has been arrested for smuggling genetic resources from the People’s Republic of China.